Levobupivacaine Hydrochloride
ApprovedSmall molecule
Levobupivacaine Hydrochloride is one of 40 small molecule programs targeting Preeclampsia. It is currently in Approved.
2
Indications
5
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
117 competitors in Preeclampsia
#DrugCompanyPhaseTrials
1Plaquenil
Alnylam PharmaceuticalsPhase 3
Folvite
Eli LillyPhase 3
Nexium
DDexcel Pharma Technologies Ltd.
Phase 3
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pitocin
RRetrophin
Phase 3
Glucophage
Boehringer IngelheimPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Low-Molecular-Weight Heparin
Daiichi SankyoPhase 3
Soliris
AstraZenecaPhase 2
No Drug
Daiichi SankyoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness1 trial
The Pharmacokinetics and Effectiveness of Local LevoBupivacaine Injection on Primary Total Joint Replacement Model.
Completed·—·N/A·NCT03258697·90 enrolled
Dexamethasone1 trial
Effect of Topically Administered Levobupivacaine- Fentanyl Versus Levobupivacaine- Dexamethasone Combination in the Control of Pain After Endoscopic Sinus Surgery
Unknown status·—·Phase 2/3·NCT05145543·80 enrolled
Acute Postoperative Pain1 trial
Laryngospasm1 trial
Levobupivacaine vs Levobupivacaine + Dexmedetomidine Infiltration for Post-tonsillectomy Analgesia and Laryngospasm in Pediatric Patients
Completed·—·Phase 1/2·NCT04113720·90 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- KKAT General Hospital